Phase I/II study of bi-weekly XELIRI plus bevacizumab treatment in patients with metastatic colorectal cancer resistant to oxaliplatin-based first-line chemotherapy
暂无分享,去创建一个
Y. Doki | M. Mori | T. Mizushima | M. Ikeda | Hirofumi Yamamoto | T. Kudo | J. Nishimura | K. Murata | Ho Min Kim | T. Hata | Takeshi Kato | M. Fukunaga | C. Matsuda | Toshinori Sueda | H. Kim